AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00776724
Drug: E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II+ ERCC1- : Epi 45mg/m2 iv/ Cis 35mg/m2 24 hrs iv infusion day 1 and 8.~Tau+ topo II- ERCC1+ : Vin 25mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II- ERCC1- : Cis 35mg/m2 24 hrs infusion / Vin 25mg/m2 iv day 1 and 8.~Tau- topo II+ ERCC1+ : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II+ ERCC1- : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II- ERCC1+ : Tax 35mg/m2 1hr infusion / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau- topo II- ERCC1- : Tax 35mg/m2 1hr infusion / Cis 35mg/m2 24 hrs infusion day 1 and 8.
Trial: NCT00507091
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous infusion
Trial: NCT00945425
Drug: AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule, once or twice daily, 7 days
Trial: NCT00945425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule, once or twice daily, 7 days
Trial: NCT02728622
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel or pegylated liposomal doxorubicin
Trial: NCT04250922
Drug: LAM561
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in Arm B will receive orally LAM561 during the Chemoradiation Phase.~Subjects in Arm B will receive LAM561 orally during the Maintenance (Adjuvant) Phase. Patients will continue to be administered with LAM561/Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression as defined by RANO criteria, unacceptable toxicity, or refusal to continue study treatment.
Trial: NCT01047670
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
Trial: NCT00393354
Drug: MK0663, Etoricoxib / Duration of Treatment : 12 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00393354
Drug: Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03708848
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic for H. pylori eradication
Trial: NCT03708848
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic for H. pylori eradication
Trial: NCT01638364
Drug: alcoholic beverage
RxNorm normalized name: Alcoholic beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An appropriate amount of 95% USP ethyl alcohol will be mixed in orange juice and tonic water to obtain a drink equivalent to 3-5 standard drinks. The beverage will be consumed over a period of 15 minutes.
Trial: NCT02183142
Drug: Mobic, China, 7.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183142
Drug: Mobic, Germany, 7.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01733316
Drug: RP103
RxNorm normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01733316
Drug: Cystagon®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01333033
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01333033
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00646789
Drug: Comparator: MK0633
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive single 50mg oral dose with follow-up observation for 5 weeks.
Trial: NCT00659750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01558739
Drug: INC424
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.
Trial: NCT00947011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet 100 mg once a day
Trial: NCT01475188
Drug: Allergovit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: commercially available grass pollen allergoid (100%), concentration A (1000 TU/ml, therapeutic units/ml)concentration B (10000 TU/ml).Patients were given subcutaneous injections with initial dose of 0.1 ml (concentration A) was increased once a 7 (+7) days until the highest tolerated dose (0.6, concentration B) was reached and SIT was continued with injections once every 4 - 6 weeks up to two years.
Trial: NCT01135290
Drug: HP828-101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02717273
Drug: extended
RxNorm normalized name: Extended Tip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: extended three-day course of antibiotics
Trial: NCT03764085
Drug: Rheosorbilact®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
Trial: NCT03764085
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
Trial: NCT00802087
Drug: hydrocodone
RxNorm normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended Release tablet
Trial: NCT00802087
Drug: hydrocodone & acetaminophen combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Release tablet, hydrocodone and acetaminophen combination product
Trial: NCT00500409
Drug: Osteoform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days
Trial: NCT00500409
Drug: SHELCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days
Trial: NCT04037566
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A cytotoxic chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
Trial: NCT00804609
Drug: DepoDur following spinal anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants underwent an elective cesarean delivery with a combined spinal/epidural. All patients received 12 mg hyperbaric bupivacaine with 20 mcg fentanyl administered intrathecally. No local anesthetic was administered through the catheter. The combined spinal-epidural was performed at the L2/L3 or L3/L4 interspace and the intrathecal dose was injected over 5-10 s. A multiple orifice epidural catheter was threaded 5 cm into the epidural space.~Provided delivery had occurred 60 minutes after the intrathecal dose patients received EREM 8 mg (DepoDur™) through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug.
Trial: NCT00132509
Drug: NINDS
RxNorm normalized name: The full generic name for the drug abbreviation 'NINDS' is not readily available. NINDS stands for the National Institute of Neurological Disorders and Stroke, which is a division of the National Institutes of Health (NIH) in the United States. It is not a drug or medication name.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase : 0.9mg/kg over 60 minutes
Trial: NCT03561753
Drug: Group A (the standard 2HRZE/4HR regimen）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin. The six-month regimen is the standard regimen for the treatment of drug-susceptible tuberculosis recommended by WHO.
Trial: NCT03561753
Drug: Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PRS regimen I（new short course PRS regimen） is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.Comparison of Standard Regimen：The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
Trial: NCT02305888
Drug: LEO 43204
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment of actinic keratosis
Trial: NCT04526509
Drug: GSK3901961
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3901961 as an IV infusion.
Trial: NCT02008110
Drug: Standard treatment strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, diuretics, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, statins, omega-3 polyunsaturated fatty acids, digoxin, nitrates and vasoactive group).
Trial: NCT03588390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to low strength tablet
Trial: NCT03588390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to middle strength tablet
Trial: NCT03588390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to high strength tablet
Trial: NCT00603343
Drug: Mictonetten 5 mg, coated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)
Trial: NCT00603343
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo corresponding to body weight
Trial: NCT01164033
Drug: RO5045337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT04526509
Drug: GSK3845097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3845097 as an IV infusion.
Trial: NCT04526509
Drug: GSK4427296
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK4427296 as an IV infusion.
Trial: NCT04526509
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
Trial: NCT01266096
Drug: PET scan with 124I-cRGDY-PEG-dots
RxNorm normalized name: D3 Dots
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five (5) patients with newly diagnosed or recurrent melanoma, and 18 malignant brain tumor patients (surgical (n=13) or non-surgical candidates (n=5)). Patients with either primary or metastatic brain tumors, will be i.v. injected with approximately 5 mCi (3.4-6.7 nanomoles) of 124I-cRGDY-PEG-dots (specific activity range 750.0 - 1450 mCi/mol) and undergo the microdosing study for purposes of collecting pharmacokinetic and dosimetry data. All studies will be performed using a dedicated scanner, which integrates a dedicated PET scanner and a spiral CT with proprietary fusion software.
Trial: NCT04421547
Drug: Standard single agent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
Trial: NCT03567057
Drug: ADS-5102, 274 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT00631111
Drug: effervescent ibuprofen tablets
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00631111
Drug: effervescent Aspirin plus Vitamin C tablets
RxNorm normalized name: aspirin Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00631111
Drug: ibuprofen tablets
RxNorm normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00631111
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03820193
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-Operative Non Opioid Pain Protocol
Trial: NCT03820193
Drug: Hydrocodon/Acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditionally used narcotic pain control
Trial: NCT03820193
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-Operative Non Opioid Pain Protocol
Trial: NCT03820193
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-Operative Non Opioid Pain Protocol
Trial: NCT01189864
Drug: Ciprofloxicin or Vigamox or other.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxicin or Vigamox or other to be used qid till epithelialized.
Trial: NCT01189864
Drug: Steroid (FML, Pred Forte, Flarex, etc.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid (FML, Pred Forte, Flarex, etc.) to be used qid to qd for 1-8 weeks.
Trial: NCT03778229
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to osimertinib (oral OD)
Trial: NCT03672500
Drug: Bupivacaine 0.5%+Epinephrine 50mc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration of the perineum with Bupivacaine 0.5%+Epinephrine 50mc
Trial: NCT00892242
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02631928
Drug: human biphasic insulin, reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: marketed product, human insulin suspension of 30% normal insulin and 70% basal (NPH) insulin
Trial: NCT02586857
Drug: ACP-196
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).
Trial: NCT04297501
Drug: Antiretroviral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants receive antiretroviral therapy to control virus replication and restore CD4+ T-cell count.
Trial: NCT05070520
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy of artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in three sentinel sites in Niger (Agadez, Gaya and Tessaoua) in 2020
Trial: NCT04657484
Drug: Medium dose prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Same as arm description
Trial: NCT04657484
Drug: Low dose prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Same as arm description
Trial: NCT00358826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dosing, 1 time daily for 12 or 24 weeks
Trial: NCT00167674
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.
Trial: NCT01420783
Drug: SAR302503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Trial: NCT04053478
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine, at applicable concentrations based on literature
Trial: NCT03999125
Drug: Ozurdex Drug Implant Product
RxNorm normalized name: Ozurdex Drug Implant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary therapy will be with Ozurdex. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Ranibizumab or Laser
Trial: NCT00000372
Drug: Glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00670475
Drug: Piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In this interventional arm gel of piroxicam (manufactured by Iran najo co,Iran), repackaged in a 60 g anonymous tubes will be administered to the patients.
Trial: NCT03822962
Drug: Ibuprofen 600Mg Tablet
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 600 mg by mouth every 8 hours scheduled in addition to standard tylenol regimen.
Trial: NCT01077206
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80mg daily versus 40mg daily, for 21 days.
Trial: NCT00210626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40,000 IU/mL/week for max of 12 weeks
Trial: NCT01227668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, once daily, 16 weeks
Trial: NCT03846271
Drug: intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an identical amount of placebo nasal spray will be applied to each subject.
Trial: NCT00939133
Drug: tretinoin microsphere 0.04% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied daily to entire face for six months
Trial: NCT00939133
Drug: vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01211769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A pill with 50mg of talcum powder, identical to the pill of naltrexone; associated to PUFAs Placebo pills (yellow liquid paraffin identical to the pills of borage seed and fish oil).
Trial: NCT04158258
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Trial: NCT01513668
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release Gel tabs 650 mg
Trial: NCT02416258
Drug: Daivobet® gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04528173
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac (0.5mg/kg; maximum 15mg intravenously) will be given at end of procedure after evaluation for hemostasis.
Trial: NCT04528173
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl (0.5-2 ug/kg intravenously) will be given intra-operatively per institutional standard clinical care.
Trial: NCT02862210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.
Trial: NCT03161028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation
Trial: NCT03001609
Drug: AC0010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi\[14C\]
Trial: NCT00667927
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See Detailed Description section for description of treatment plan.
Trial: NCT00756964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.
Trial: NCT04403100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets - 01 tablet twice daily from day 01 through day 10.
Trial: NCT01533428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Patch
Trial: NCT00882895
Drug: Solumedrol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02984683
Drug: SAR566658 (ACT14884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution Route of administration: Intravenous
Trial: NCT03118739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule administered orally, once daily for 24 weeks
Trial: NCT02231320
Drug: Berodual® Respimat® - inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01323998
Drug: 5ARI
RxNorm normalized name: 5-alpha reductase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride or Finasteride
Trial: NCT01544114
Drug: VIMOVO 250/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
Trial: NCT01544114
Drug: VIMOVO 375/20
RxNorm normalized name: Vimovo 375/20 Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months